Editorial Board About Us

Volume 6, Supplement 9

Self Assessment Post Test

Claus G Roehrborn

Role of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPH

Lower urinary tract symptoms 5-reductase inhibitors Benign prostatichyperplasia Dihydrotestosterone Primary care clinicians

AUA Guidelines and Their Impact on the Management of BPH: An Update

Steven A Kaplan

Benign prostatic hyperplasia Medical treatment Guidelines American Urological Association Symptom score

The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy

Kevin M Slawin Michael W Kattan

Benign prostatic hyperplasia Nomogram 5-reductase inhibitors Progression

Comparison of Clinical Trials With Finasteride and Dutasteride

J Curtis Nickel

Benign prostatic hyperplasia Medical therapy Finasteride Dutasteride Dihydrotestosterone 5-reductase

The Clinical Benefits of Dutasteride Treatment for LUTS and BPH

Claus G Roehrborn

Benign prostatic hyperplasia Lower urinary tract symptoms 5-reductase inhibitors Dutasteride Clinical trials

5-Alpha-Reductase: History and Clinical Importance

Leonard S Marks

Benign prostatic hyperplasia Finasteride Dutasteride Dihydrotestosterone 5-reductase Guevedoces

Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia

Benign prostatic hyperplasia Lower urinary tract symptoms Bladder outletobstruction Acute urinary retention

Introduction: 5-Alpha-Reductase Inhibition in the Treatment of LUTS and BPH: Update and Importance of Dual Inhibition of Types 1 and 2

Claus G Roehrborn